75 results on '"Relling, Mary V."'
Search Results
2. Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia
3. Palmar‐plantar erythrodysesthesia syndrome following treatment with high‐dose methotrexate or high‐dose cytarabine
4. Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics
5. Pharmacogenomics in the clinic
6. Comparable Efficacy With Varying Dosages of Glucarpidase in Pediatric Oncology Patients
7. SVSI: Fast and Powerful Set-Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits
8. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study
9. Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
10. The clinical pharmacogenetics implementation consortium (CPIC): facilitating the adoption of pharmacogenetics into routine clinical practice and the electronic health record.: 286.
11. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
12. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes
13. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics
14. Development and use of active clinical decision support for preemptive pharmacogenomics
15. Development and use of active clinical decision support for preemptive pharmacogenomics
16. Pharmacogenetically-based use of codeine in a childrenʼs hospital setting.: 261.
17. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia
18. Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations
19. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011
20. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity
21. Resumption of High-Dose Methotrexate After Acute Kidney Injury and Glucarpidase Use in Pediatric Oncology Patients
22. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia
23. Evidence for Age As a Modifier of Genetic Associations for Lipid Levels
24. Development and implementation of a pharmacist-managed clinical pharmacogenetics service
25. Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation
26. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol
27. Effect of Allopurinol Versus Urate Oxidase on Methotrexate Pharmacokinetics in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
28. Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
29. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
30. Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia
31. The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia
32. Genetic Polymorphisms in the Carbonyl Reductase 3 Gene Cbr3 and the Nad(P)H:Quinone Oxidoreductase 1 Gene Nqo1 in Patients Who Developed Anthracycline-Related Congestive Heart Failure After Childhood Cancer
33. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
34. Phase Ii Study of Topotecan in Combination With Dexamethasone, Asparaginase, and Vincristine in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse
35. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?
36. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression
37. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
38. Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
39. Pharmacogenomics: Challenges and Opportunities
40. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
41. Global gene expression as a function of germline genetic variation
42. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics
43. Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia
44. Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
45. Magnetic Fields and Leukemia
46. Moving towards individualized medicine with pharmacogenomics
47. Mechanisms of Disease: Acute Lymphoblastic Leukemia
48. Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children
49. Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia
50. Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.